Tagrisso is shaping up to be one of the company's best performers, and AZ now predicts it can reach peak of $3 billion. This will help towards chief executive Pascal Soriot achieving his ...

Developed as a treatment for patients whose cancers develop a single amino acid mutation that blocks the action of AZ’s older EGFR drug, Iressa, the FLAURA trial investigated whether Tagrisso ...